<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04210115</url>
  </required_header>
  <id_info>
    <org_study_id>3475-975</org_study_id>
    <secondary_id>2019-002006-51</secondary_id>
    <secondary_id>MK-3475-975</secondary_id>
    <secondary_id>KEYNOTE-975</secondary_id>
    <secondary_id>PHRR200210-002490</secondary_id>
    <secondary_id>205261</secondary_id>
    <nct_id>NCT04210115</nct_id>
  </id_info>
  <brief_title>Study of Pembrolizumab (MK-3475) Versus Placebo in Participants With Esophageal Carcinoma Who Are Receiving Chemotherapy and Radiation Therapy (MK-3475-975/KEYNOTE-975)</brief_title>
  <official_title>A Randomized, Double-blind, Placebo-controlled Phase 3 Trial of Pembrolizumab (MK-3475) Versus Placebo in Participants With Esophageal Carcinoma Receiving Concurrent Definitive Chemoradiotherapy (KEYNOTE 975)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Merck Sharp &amp; Dohme Corp.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Merck Sharp &amp; Dohme Corp.</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to assess the efficacy and safety of treatment with definitive
      chemoradiotherapy (dCRT) + pembrolizumab (MK-3475) compared to treatment with dCRT + placebo
      with respect to Overall Survival (OS) and Event-free survival (EFS) in:

        -  participants with esophageal squamous cell carcinoma (ESCC),

        -  participants whose tumors express Programmed Death-Ligand 1 (PD-L1) Combined Positive
           Score (CPS) ≥10, and

        -  all participants.

      The primary study hypotheses are that dCRT+ pembrolizumab is better than dCRT + placebo with
      respect to:

        -  OS in participants with ESCC,

        -  OS in participants whose tumors express PD-L1 CPS ≥10,

        -  OS in all participants,

        -  EFS in participants with ESCC,

        -  EFS in participants whose tumors express PD-L1 CPS ≥10, and

        -  EFS in all participants.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Participants receive pembrolizumab or placebo PLUS one of two chemotherapy regimens PLUS
      radiation therapy for up to approximately one year. The chemotherapy regimens are either:

        -  FP (5-fluorouracil [5-FU] + cisplatin) or

        -  FOLFOX (5-FU + oxaliplatin + leucovorin or levoleucovorin).
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">February 28, 2020</start_date>
  <completion_date type="Anticipated">February 21, 2026</completion_date>
  <primary_completion_date type="Anticipated">February 21, 2026</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Triple (Participant, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Overall Survival (OS)</measure>
    <time_frame>Up to ~72 months</time_frame>
    <description>OS is defined as the time from randomization to death from any cause.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Event-free Survival (EFS)</measure>
    <time_frame>Up to ~60 months</time_frame>
    <description>EFS is defined as the time from randomization to an event defined as local, regional, or distant recurrence of the treated esophageal cancer or death from any cause.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Number of participants with an adverse event (AE)</measure>
    <time_frame>Up to ~15 months</time_frame>
    <description>An AE is any untoward medical occurrence in a participant that is temporally associated with the use of study treatment, whether or not considered related to the study treatment.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of participants discontinuing study treatment due to an adverse event (AE)</measure>
    <time_frame>Up to ~12 months</time_frame>
    <description>An AE is any untoward medical occurrence in a participant that is temporally associated with the use of study treatment, whether or not considered related to the study treatment.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">600</enrollment>
  <condition>Esophageal Squamous Cell Carcinoma (ESCC)</condition>
  <condition>Siewert Type I Adenocarcinoma of the Esophagogastric Junction (EGJ)</condition>
  <condition>Esophageal Adenocarcinoma (EAC)</condition>
  <arm_group>
    <arm_group_label>Pembrolizumab+FP or FOLFOX Therapy+Radiotherapy</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants receive pembrolizumab 200 mg on Day 1 of each 3-week cycle for 8 cycles followed by pembrolizumab 400 mg on Day 1 of each 6-week cycle for 5 cycles PLUS either:
FP therapy: cisplatin 75 mg/m^2 on Day 1 of Weeks 1, 5, 8 and 11 PLUS 5-fluorouracil (5-FU)] 1000 mg/m^2 per day on Days 1-4 of Weeks 1, 5, 8 and 11 OR 800 mg/m^2/day on each of Days 1-5 at Weeks 1, 5, 8, and 11 PLUS radiotherapy (either 50 Gray [Gy] in 25 fractions OR 60 Gy in 30 fractions) on Days 1-5 of each 3-week cycle OR
FOLFOX therapy: oxaliplatin 85 mg/m^2 AND either leucovorin 400 mg/m^2 OR levoleucovorin 200 mg/m^2 on Day 1 of Weeks 1, 3, 5, 7, 9 and 11 PLUS either 5-FU 400 mg/m^2 on Day 1 of Weeks 1, 3, 5, 7, 9 and 11 OR 5-FU 800 mg/m^2 per day on Days 1 and 2 of Weeks 1, 3, 5, 7, 9 and 11 PLUS radiotherapy (50 Gy in 25 fractions) on Days 1-5 of each 3-week cycle.
All treatments except radiotherapy are given by intravenous (IV) infusion. Total treatment duration is approximately 1 year.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo+FP or FOLFOX Therapy+Radiotherapy</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Participants receive placebo on Day 1 of each 3-week cycle for 8 cycles followed by placebo on Day 1 of each 6-week cycle for 5 cycles PLUS either:
FP therapy: cisplatin 75 mg/m^2 on Day 1 of Weeks 1, 5, 8 and 11 PLUS 5-FU 1000 mg/m^2 per day on Days 1-4 of Weeks 1, 5, 8 and 11 OR 800 mg/m^2/day on each of Days 1-5 at Weeks 1, 5, 8, and 11 PLUS radiotherapy (either 50 Gy in 25 fractions OR 60 Gy in 30 fractions) on Days 1-5 of each 3-week cycle OR
FOLFOX therapy: oxaliplatin 85 mg/m^2 AND either leucovorin 400 mg/m^2 OR levoleucovorin 200 mg/m^2 on Day 1 of Weeks 1, 3, 5, 7, 9 and 11 PLUS either 5-FU 400 mg/m^2 on Day 1 of Weeks 1, 3, 5, 7, 9 and 11 OR 5-FU 800 mg/m^2 per day on Days 1 and 2 of Weeks 1, 3, 5, 7, 9 and 11 PLUS radiotherapy (50 Gy in 25 fractions) on Days 1-5 of each 3-week cycle.
All treatments except radiotherapy are given by IV infusion. Total treatment duration is approximately 1 year.</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>pembrolizumab</intervention_name>
    <description>IV infusion</description>
    <arm_group_label>Pembrolizumab+FP or FOLFOX Therapy+Radiotherapy</arm_group_label>
    <other_name>MK-3475</other_name>
    <other_name>KEYTRUDA®</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>placebo</intervention_name>
    <description>IV infusion</description>
    <arm_group_label>Placebo+FP or FOLFOX Therapy+Radiotherapy</arm_group_label>
    <other_name>Normal saline solution</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>cisplatin</intervention_name>
    <description>IV infusion</description>
    <arm_group_label>Pembrolizumab+FP or FOLFOX Therapy+Radiotherapy</arm_group_label>
    <arm_group_label>Placebo+FP or FOLFOX Therapy+Radiotherapy</arm_group_label>
    <other_name>PLATINOL®</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>5-FU</intervention_name>
    <description>IV infusion</description>
    <arm_group_label>Pembrolizumab+FP or FOLFOX Therapy+Radiotherapy</arm_group_label>
    <arm_group_label>Placebo+FP or FOLFOX Therapy+Radiotherapy</arm_group_label>
    <other_name>ADRUCIL®</other_name>
  </intervention>
  <intervention>
    <intervention_type>Radiation</intervention_type>
    <intervention_name>radiotherapy</intervention_name>
    <description>external radiation</description>
    <arm_group_label>Pembrolizumab+FP or FOLFOX Therapy+Radiotherapy</arm_group_label>
    <arm_group_label>Placebo+FP or FOLFOX Therapy+Radiotherapy</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>leucovorin</intervention_name>
    <description>IV infusion</description>
    <arm_group_label>Pembrolizumab+FP or FOLFOX Therapy+Radiotherapy</arm_group_label>
    <arm_group_label>Placebo+FP or FOLFOX Therapy+Radiotherapy</arm_group_label>
    <other_name>calcium folinate</other_name>
    <other_name>folinic acid</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>levoleucovorin</intervention_name>
    <description>IV infusion</description>
    <arm_group_label>Pembrolizumab+FP or FOLFOX Therapy+Radiotherapy</arm_group_label>
    <arm_group_label>Placebo+FP or FOLFOX Therapy+Radiotherapy</arm_group_label>
    <other_name>FUSILEV®</other_name>
    <other_name>calcium levofolinate</other_name>
    <other_name>levofolinic acid</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>oxaliplatin</intervention_name>
    <description>IV infusion</description>
    <arm_group_label>Pembrolizumab+FP or FOLFOX Therapy+Radiotherapy</arm_group_label>
    <arm_group_label>Placebo+FP or FOLFOX Therapy+Radiotherapy</arm_group_label>
    <other_name>ELOXATIN®</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Has Siewert Type I adenocarcinoma of the EGJ, or EAC

          -  Is deemed suitable for dCRT

          -  Is ineligible for curative surgery based on the documented opinion of a qualified
             medical/surgical/radiation oncologist

          -  Is not expected to require tumor resection during the course of the study

          -  Has an Eastern Cooperative Oncology Group (ECOG) performance status of 0 to 1 within 3
             days of the first dose of study treatment.

          -  Has adequate organ function

          -  Male participants must use adequate contraception (a male condom plus partner use of
             an additional contraceptive method) unless confirmed to be azoospermic (vasectomized
             or secondary to medical cause) during the study treatment period and through 180 days
             after the last dose of chemotherapy or through 120 days after the last dose of
             pembrolizumab, whichever is greater

          -  Female participants who are a Woman of Childbearing Potential (WOCBP) must use
             contraception that is highly effective (with a failure rate of &lt;1% per year), with low
             user dependency, or be abstinent from heterosexual intercourse as their preferred and
             usual lifestyle, during the study treatment period through 180 days after the last
             dose of chemotherapy or 120 days after the last dose of pembrolizumab, whichever is
             greater, and agree not to donate eggs to others or freeze/store for her own use for
             the purpose of reproduction during this period

          -  Female participants must not be pregnant or breastfeeding

        Exclusion Criteria:

          -  Has direct invasion of tumor into adjacent organs such as the aorta or trachea

          -  Has had major surgery other than for insertion of a feeding tube, open biopsy, or
             significant traumatic injury within 28 days prior to randomization, or anticipates the
             need for major surgery during study treatment

          -  Has had weight loss of &gt;20% in the previous 3 months

          -  Has had prior chemotherapy or radiotherapy for esophageal cancer

          -  Has had a myocardial infarction within the past 6 months

          -  Has severe congestive heart failure

          -  Has received prior therapy with an anti-programmed cell death-1 (anti-PD-1),
             anti-programmed cell death-ligand 1 (anti-PD-L1), or anti-programmed cell death-ligand
             2 (anti-PD-L2) agent or with an agent directed to another stimulatory or co-inhibitory
             T-cell receptor (e.g. cytotoxic T-lymphocyte-associated protein 4 [CTLA-4], OX-40,
             CD137)

          -  Has received a live vaccine within 30 days prior to the first dose of study treatment

          -  Has received any prior systemic anticancer therapy for esophageal cancer including
             investigational agents

          -  Has not recovered from all adverse events (AEs) due to previous non-anticancer
             therapies to ≤Grade 1 or Baseline

          -  Has a diagnosis of immunodeficiency or is receiving chronic systemic steroid therapy
             or any other form of immunosuppressive therapy within 7 days prior the first dose of
             study treatment

          -  Has a known additional malignancy that is progressing or has required active treatment
             within the past 3 years. Note: Participants with basal cell carcinoma of the skin,
             squamous cell carcinoma of the skin, or carcinoma in situ (e.g. breast carcinoma,
             cervical cancer in situ) that have undergone potentially curative therapy are not
             excluded from the study. Participants with localized prostate cancer that has
             undergone potentially curative treatment can be enrolled in the study.

          -  Has severe hypersensitivity (≥Grade 3) to pembrolizumab, any of the study chemotherapy
             agents, or their excipients

          -  Has an active autoimmune disease that has required systemic treatment in past 2 years

          -  Has a history of (non-infectious) pneumonitis that required steroids or has current
             pneumonitis

          -  Has an active infection requiring systemic therapy

          -  Has a known history of human immunodeficiency virus (HIV) infection

          -  Has a known history of Hepatitis B or known active Hepatitis C virus infection

          -  Has a known history of active tuberculosis (TB; Bacillus tuberculosis)

          -  Is pregnant or breastfeeding or expecting to conceive or father children within the
             projected duration of the study, starting with the screening visit through 120 days
             after the last dose of study treatment (180 days for participants receiving cisplatin
             who are breastfeeding)

          -  Has had an allogenic tissue/solid organ transplant
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Medical Director</last_name>
    <role>Study Director</role>
    <affiliation>Merck Sharp &amp; Dohme Corp.</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Toll Free Number</last_name>
    <phone>1-888-577-8839</phone>
    <email>Trialsites@merck.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>University Medical Center ( Site 0035)</name>
      <address>
        <city>New Orleans</city>
        <state>Louisiana</state>
        <zip>70112</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>504-702-3574</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Greater Baltimore Medical Center ( Site 0031)</name>
      <address>
        <city>Baltimore</city>
        <state>Maryland</state>
        <zip>21204</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>443-849-3122</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Henry Ford Cancer Center ( Site 0685)</name>
      <address>
        <city>Detroit</city>
        <state>Michigan</state>
        <zip>48202</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>313-916-0482</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Stephenson Cancer Center ( Site 0044)</name>
      <address>
        <city>Oklahoma City</city>
        <state>Oklahoma</state>
        <zip>73104</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>405-271-8001</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Oregon Health &amp; Science University Center for Health &amp; Healing 2- CHH2 ( Site 0060)</name>
      <address>
        <city>Portland</city>
        <state>Oregon</state>
        <zip>97239</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>503-494-1080</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Cancer Care Northwest - Spokane Valley ( Site 0036)</name>
      <address>
        <city>Spokane Valley</city>
        <state>Washington</state>
        <zip>99216</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>509-228-1689</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>AZ Delta ( Site 0165)</name>
      <address>
        <city>Roeselare</city>
        <state>West-Vlaanderen</state>
        <zip>8800</zip>
        <country>Belgium</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+3251237215</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Sociedad de Investigaciones Medicas Limitadas ( Site 0106)</name>
      <address>
        <city>Temuco</city>
        <state>Araucania</state>
        <zip>4810469</zip>
        <country>Chile</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+56994443272</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Hospital Regional de Concepcion ( Site 0105)</name>
      <address>
        <city>Concepcion</city>
        <state>Biobio</state>
        <zip>4070038</zip>
        <country>Chile</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+56992567286</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Centro de Cancer Nuestra Senora de la Esperanza ( Site 0104)</name>
      <address>
        <city>Santiago</city>
        <state>Region Metropolitana De Santiago</state>
        <zip>8330024</zip>
        <country>Chile</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+56991612199</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>900 Hospital of the Joint ( Site 0509)</name>
      <address>
        <city>Fuzhou</city>
        <state>Fujian</state>
        <zip>350025</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+8613774562945</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Hubei Cancer Hospital ( Site 0514)</name>
      <address>
        <city>Wuhan</city>
        <state>Hubei</state>
        <zip>430079</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>13907174495</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>The Affiliated Hospital of Xuzhou Medical University ( Site 0522)</name>
      <address>
        <city>Xuzhou</city>
        <state>Jiangsu</state>
        <zip>221002</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>15895236960</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Affiliated Hospital of Jiangsu University ( Site 0524)</name>
      <address>
        <city>Zhenjiang</city>
        <state>Jiangsu</state>
        <zip>212000</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+8651185023852</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Shanghai Chest Hospital ( Site 0503)</name>
      <address>
        <city>Shangai</city>
        <state>Shanghai</state>
        <zip>200030</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>021-22200000</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Shanghai Chest Hospital ( Site 0501)</name>
      <address>
        <city>Shanghai</city>
        <state>Shanghai</state>
        <zip>200030</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>021-22200000</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Zhongshan Hospital Fudan University ( Site 0502)</name>
      <address>
        <city>Shanghai</city>
        <state>Shanghai</state>
        <zip>200032</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+86 13817076800</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Sir Run Run Shaw Hospital ( Site 0523)</name>
      <address>
        <city>Hangzhou</city>
        <state>Zhejiang</state>
        <zip>310018</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+8657186090073</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Rigshospitalet ( Site 0199)</name>
      <address>
        <city>Copenhagen</city>
        <state>Hovedstaden</state>
        <zip>2100</zip>
        <country>Denmark</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+4535450818</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Odense Universitetshospital ( Site 0200)</name>
      <address>
        <city>Odense</city>
        <state>Syddanmark</state>
        <zip>5000</zip>
        <country>Denmark</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+4540467104</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>SA Pohja-Eesti Regionaalhaigla ( Site 0201)</name>
      <address>
        <city>Tallinn</city>
        <state>Harjumaa</state>
        <zip>13419</zip>
        <country>Estonia</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+3726171245</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>SA Tartu Ulikooli Kliinikum ( Site 0202)</name>
      <address>
        <city>Tartu</city>
        <state>Tartumaa</state>
        <zip>51014</zip>
        <country>Estonia</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+3727318815</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Institut Sainte Catherine ( Site 0228)</name>
      <address>
        <city>Avignon</city>
        <state>Provence-Alpes-Cote-d'Azur</state>
        <zip>84918</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+33490276268</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>CHD Vendee ( Site 0227)</name>
      <address>
        <city>La Roche sur Yon</city>
        <state>Vendee</state>
        <zip>85925</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+0033251446161</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Medi-K Cayala ( Site 0124)</name>
      <address>
        <city>Guatemala</city>
        <zip>01016</zip>
        <country>Guatemala</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+50255505555</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Princess Margaret Hospital. ( Site 0542)</name>
      <address>
        <city>Hong Kong</city>
        <country>Hong Kong</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>29902393</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Queen Mary Hospital ( Site 0541)</name>
      <address>
        <city>Pokfulam</city>
        <country>Hong Kong</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>22554216</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Orszagos Onkologiai Intezet ( Site 0263)</name>
      <address>
        <city>Budapest</city>
        <zip>1122</zip>
        <country>Hungary</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+3612248600</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Debreceni Egyetem Klinikai Kozpont ( Site 0261)</name>
      <address>
        <city>Debrecen</city>
        <zip>4032</zip>
        <country>Hungary</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+3652255840</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>ASST Papa Giovanni XXIII ( Site 0296)</name>
      <address>
        <city>Bergamo</city>
        <zip>24127</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+390352673694</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Azienda Ospedaliero Universitaria Pisana - Presidio Santa Chiara ( Site 0294)</name>
      <address>
        <city>Pisa</city>
        <zip>56126</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+39050992455</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Policlinico Universitario A. Gemelli ( Site 0297)</name>
      <address>
        <city>Roma</city>
        <zip>00168</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+390696734844</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Chonnam National University Hwasun Hospital ( Site 0625)</name>
      <address>
        <city>Hwasun Gun</city>
        <state>Jeonranamdo</state>
        <zip>58128</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+8218990000</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>National Cancer Center ( Site 0626)</name>
      <address>
        <city>Goyang-si</city>
        <state>Kyonggi-do</state>
        <zip>10408</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+8215888110</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Severance Hospital Yonsei University Health System ( Site 0624)</name>
      <address>
        <city>Seoul</city>
        <state>Seoul-teukbyeolsi [Seoul]</state>
        <zip>03722</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+82 2 2228 1004</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Asan Medical Center ( Site 0623)</name>
      <address>
        <city>Seoul</city>
        <state>Seoul-teukbyeolsi [Seoul]</state>
        <zip>05505</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+8216887575</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Samsung Medical Center ( Site 0622)</name>
      <address>
        <city>Seoul</city>
        <state>Seoul-teukbyeolsi [Seoul]</state>
        <zip>06351</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+82215993114</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Korea University Guro Hospital ( Site 0621)</name>
      <address>
        <city>Seoul</city>
        <state>Seoul-teukbyeolsi [Seoul]</state>
        <zip>08308</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+8215779966</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Kaluga Regional Clinical Oncology Center ( Site 0424)</name>
      <address>
        <city>Kaluga</city>
        <state>Kaluzskaja Oblast'</state>
        <zip>248007</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+79200900576</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>FSAI Treatment and Rehabilitation Centre of the MoH and SD of RF ( Site 0429)</name>
      <address>
        <city>Moscow</city>
        <state>Moskva</state>
        <zip>125367</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+79264375889</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>SBHI Samara Regional Clinical Oncology Dispensary ( Site 0420)</name>
      <address>
        <city>Samara</city>
        <state>Samarskaya Oblast</state>
        <zip>443031</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+79272143459</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Pavlov First Saint Petersburg State Medical University ( Site 0426)</name>
      <address>
        <city>St. Petersburg</city>
        <state>Sankt-Peterburg</state>
        <zip>197022</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+9811957915</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Medical institute named after Berezin Sergey ( Site 0417)</name>
      <address>
        <city>St. Petersburg</city>
        <state>Sankt-Peterburg</state>
        <zip>197758</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+78122440024</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Sverdlovsk Regional Oncology Hospital ( Site 0411)</name>
      <address>
        <city>Ekaterinburg</city>
        <state>Sverdlovskaya Oblast'</state>
        <zip>620036</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+73433561505</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Republican Clinical Oncology Dispensary of Tatarstan MoH ( Site 0412)</name>
      <address>
        <city>Kazan</city>
        <state>Tatarstan, Respublika</state>
        <zip>420029</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+78435257346</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>National Cheng Kung University Hospital ( Site 0645)</name>
      <address>
        <city>Tainan</city>
        <zip>704</zip>
        <country>Taiwan</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+88662353535</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>National Taiwan University Hospital ( Site 0641)</name>
      <address>
        <city>Taipei</city>
        <zip>10002</zip>
        <country>Taiwan</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+88622312345667680</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Medeniyet University Goztepe Egitim ve Arastırma Hast. Merdivenkoy ( Site 0451)</name>
      <address>
        <city>Istanbul</city>
        <zip>34722</zip>
        <country>Turkey</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+905063509061</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Ege Universitesi Tıp Fakultesi ( Site 0457)</name>
      <address>
        <city>Izmir</city>
        <zip>35040</zip>
        <country>Turkey</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+905325566065</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Izmir Katip Celebi Universitesi Ataturk Egitim ve Arastirma Hastanesi ( Site 0458)</name>
      <address>
        <city>Izmir</city>
        <zip>35360</zip>
        <country>Turkey</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+905324078648</phone>
    </contact>
  </location>
  <location_countries>
    <country>Belgium</country>
    <country>Chile</country>
    <country>China</country>
    <country>Denmark</country>
    <country>Estonia</country>
    <country>France</country>
    <country>Guatemala</country>
    <country>Hong Kong</country>
    <country>Hungary</country>
    <country>Italy</country>
    <country>Korea, Republic of</country>
    <country>Russian Federation</country>
    <country>Taiwan</country>
    <country>Turkey</country>
    <country>United States</country>
  </location_countries>
  <verification_date>July 2020</verification_date>
  <study_first_submitted>December 20, 2019</study_first_submitted>
  <study_first_submitted_qc>December 20, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">December 24, 2019</study_first_posted>
  <last_update_submitted>July 23, 2020</last_update_submitted>
  <last_update_submitted_qc>July 23, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">July 24, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Programmed Cell Death-1 (PD1, PD-1)</keyword>
  <keyword>Programmed Death-Ligand 1 (PDL1, PD-L1)</keyword>
  <keyword>Programmed Death-Ligand 2 (PDL2, PD-L2)</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Carcinoma</mesh_term>
    <mesh_term>Adenocarcinoma</mesh_term>
    <mesh_term>Esophageal Squamous Cell Carcinoma</mesh_term>
    <mesh_term>Esophageal Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Calcium, Dietary</mesh_term>
    <mesh_term>Leucovorin</mesh_term>
    <mesh_term>Oxaliplatin</mesh_term>
    <mesh_term>Pembrolizumab</mesh_term>
    <mesh_term>Calcium</mesh_term>
    <mesh_term>Levoleucovorin</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
    <ipd_description>http://engagezone.msd.com/doc/ProcedureAccessClinicalTrialData.pdf</ipd_description>
    <ipd_url>http://engagezone.msd.com/ds_documentation.php</ipd_url>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

